Amelioration of Systemic Amyloidosis by Blocking IL-17A and Not by IL-17F, and Arteriosclerosis by Blocking Both IL-17A and IL-17F in an Inflammatory Skin Mouse Model
Authors:
- Takehisa NakanishiTNTakehisa Nakanishi
- Shohei IidaSIShohei Iida
- Masako IchishiMIMasako Ichishi
- Makoto KondoMKMakoto Kondo
- Mai NishimuraMNMai Nishimura
- Ayaka IchikawaAIAyaka Ichikawa
- Yoshiaki MatsushimaYMYoshiaki Matsushima
- Yoichiro IwakuraYIYoichiro Iwakura
- Masatoshi WatanabeMasatoshi Watanabe
- Keiichi YamanakaKYKeiichi Yamanaka
Open Access
- 29 October 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (21) , 11617
Abstract
There are comorbidities and complications in atopic dermatitis and psoriasis that often occur after the appearance of skin inflammation. Statistically, data show that patients with psoriasis and atopic dermatitis have a shorter life expectancy than patients without psoriatic dermatitis, due to the occurrence of arteriosclerosis, myocardial infarction, and cerebral infarction. Many types of skin inflammation are treated with various antibody preparations, and marked improvement in patients’ quality of life can be achieved. The next theme is to understand the pathogenesis of arteriosclerosis, myocardial infarction, stroke, and other complications associated with dermatitis and to find treatments and drugs to reduce their occurrence. The skin, a crucial immune organ, generates large amounts of inflammatory cytokines in response to various stimuli, leading to systemic inflammation and potential damage to internal organs. The link between inflammatory skin conditions like psoriasis and atopic dermatitis with serious health complications such as vascular disorders and systemic amyloidosis has been increasingly recognized. In psoriasis, biological treatments targeting Interleukin (IL)-17A, a key cytokine, have shown promise in reducing cardiovascular risks. Recent developments include treatments that target both IL-17A and IL-17F in the psoriasis field, though each cytokine’s impact on internal organ damage is still under debate. Among visceral complications secondary to dermatitis, systemic amyloidosis and atherosclerosis have been reported to be controlled by suppressing IL-17 in the early stages of dermatitis. Still, it remains unclear whether suppressing IL-17 prevents organ damage in the late stages of persistent severe dermatitis. A study using a long-lasting dermatitis mouse model that overexpressed human caspase-1 in keratinocytes (Kcasp1Tg) investigated the effects of deleting IL-17A and IL-17F on visceral complications. Cross-mating Kcasp1Tg with IL-17A-, IL-17F-, and IL-17AF-deficient mice assessed the skin and visceral organs histologically, and RT-PCR analysis of aortic sclerosis markers was performed. Despite less improvement in dermatitis, deletion of IL-17A in Kcasp1Tg mice showed promising results in reducing multiple organ amyloidosis. On the other hand, the effect was observed in both IL-17A and IL-17F deleted mice for aortic sclerosis. The inhibition of IL-17A and IL-17F was suggested to reduce the risk of developing comorbidities in internal organs. IL-17A and IL-17F were found to act similarly or produce very different results, depending on the organ.Keywords
Funding Information
- Japan Society for the Promotion of Science (22K08379)
This publication has 56 references indexed in Scilit:
- Structural cell heterogeneity underlies the differential contribution of IL-17A, IL-17F and IL-23 to joint versus skin chronic inflammationAutoimmunity Reviews, 2024
- Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease MechanismsCurrent Rheumatology Reports, 2022
- Bimekizumab for the Treatment of PsoriasisDrugs, 2021
- Apolipoproteins L control cell death triggered by TLR3/TRIF signaling in dendritic cellsEuropean Journal of Immunology, 2016
- “Inflammatory skin march”: IL-1–mediated skin inflammation, atopic dermatitis, and psoriasis to cardiovascular eventsJournal of Allergy and Clinical Immunology, 2015
- Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With PsoriasisArchives of Dermatology, 2012
- A comprehensive summary of LL-37, the factotum human cathelicidin peptideCellular Immunology, 2012
- Cytokine-Producing Dendritic Cells in the Pathogenesis of Inflammatory Skin DiseasesJournal of Clinical Immunology, 2009
- Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986-2006Journal of the American Academy of Dermatology, 2009
- The function of apolipoproteins LCellular and Molecular Life Sciences, 2006